Royalty Pharma plc (RPRX) stock
RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3060% above fair value
$69.31+0.34 (+0.49%)
Close on Nov 13, 2026Market cap $39.85BP/E 48.8Yield –
Royalty Pharma enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Royalty Pharma's enterprise value was $50.12B on Nov 11, 2026, against $34.10B a year earlier. Over the last 5 years it ranged from $23.68B to $50.12B, with a median of $30.01B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $50.12B | +50.5% |
| 2025 | Dec 31, 2025 | $33.31B | +32.2% |
| 2024 | Dec 31, 2024 | $25.20B | +3.0% |
| 2023 | Dec 29, 2023 | $24.48B | -24.1% |
| 2022 | Dec 30, 2022 | $32.23B | +0.9% |
| 2021 | Dec 31, 2021 | $31.93B | – |
See a number that looks wrong?